SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is capturing community attention as the project emphasizes long-term culture building, organic growth, and its alignment with cannabis advocacy ahead of 4/20. Participants are actively debating the token's potential for real-world integration in the cannabis space while closely monitoring community-led initiatives and social engagement.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is facing extreme volatility and intense community backlash after a massive, rapid price rally was followed by a sharp collapse, leading to widespread accusations of an insider-led rug pull. While some traders are actively seeking short-term gains through dead cat bounces and technical setups, many community members are warning of a scam due to the highly concentrated token supply and ongoing investigations into potential market manipulation.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging as a legacy project with deep roots in early internet culture, drawing significant attention for its historical status as the original crypto satire from 2011. The community is heavily focused on its long-standing lore, verifiable origins, and recent on-chain presence, with many investors viewing its unique narrative as a differentiator in the crowded memecoin market.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors weigh a critical BlueBird 7 satellite launch against a structured share sale by major stakeholder Rakuten. While community sentiment is heavily focused on the potential for a short squeeze and long-term constellation deployment, discussions are currently dominated by debates over launch cadence, the impact of the equity offering, and the company's ability to scale manufacturing to meet future targets.

Asteroid Shiba is inspired by a real-life event where a Shiba Inu plush toy named "Asteroid" served as a zero-gravity indicator during the Polaris Dawn mission. This connection to space travel gives it a narrative that's both whimsical and grounded in a tangible event, differentiating it from other meme coins which might rely solely on internet culture or celebrity endorsements.  The coin's mascot, the zero-gravity Shiba Inu, was designed by a young cancer survivor, Liv Perrotto, adding a layer of emotional connection and human interest story that's rare in the crypto space. This backstory not only provides a unique selling point but also a community rallying point.

Asteroid Shiba

Asteroid Shiba is generating significant buzz as a high-volatility memecoin following a rapid price surge, sparking intense debate among community members over whether it represents a sustainable growth opportunity or a speculative pump-and-dump cycle. While many traders are celebrating aggressive gains and comparing it to other viral tokens, others remain cautious, questioning the legitimacy of its rapid movement and advising others to lock in profits.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing significant market interest driven by institutional developments, including its inclusion in upcoming CME futures and active adoption across various DeFi and gaming protocols. Community sentiment is notably polarized, with many investors aggressively accumulating during dips and citing long-term potential, while others express caution regarding price volatility and project comparisons.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

Investors are actively rallying behind RETIRE as a community-driven alternative to traditional retirement plans, frequently discussing its potential for life-changing gains and long-term accumulation. The conversation centers on the project's ability to remain resilient during market volatility, with participants framing it as a movement against the established financial system.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as investors react to a recent corporate rebranding and executive shifts while monitoring clinical progress for its MDD and GAD treatment pipeline. Community sentiment is polarized, with some traders optimistic about the potential for regulatory tailwinds and upcoming trial data, while others remain skeptical due to the company's history of dilution and previous share price performance.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz as the community actively rallies behind its humorous branding and ongoing engagement efforts, including poker events and social media campaigns. Investors are debating its long-term potential while the community remains highly vocal about the project's staying power and retail-driven mission.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility as the community debates whether the asset is staging a breakout or entering a bear trap, with traders closely monitoring geopolitical tensions in the Middle East and speculative talk of peace deals. Sentiment remains deeply polarized, as investors weigh ongoing accumulation by institutional "whales" against bearish technical patterns and concerns regarding potential liquidations in the futures market.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>REPL came under pressure after the FDA issued a second Complete Response Letter for RP1 with nivolumab in anti-PD-1-failed melanoma.</li><li>HOTH declined after a $2 million stock offering, along with attached warrants, raised dilution concerns despite recent pipeline updates.</li><li>ONCO is on a major slide after its reverse stock split, while its pending all-stock acquisition of Realbotix has yet to improve investor sentiment.</li></ul>Shares of Replimune (REPL), Hoth Therapeutics (HOTH), and Onconetix (ONCO) hit fresh 52-week lows on Monday following an FDA setback, a discounted offering, and a reverse split that underscored listing-compliance pressure.&nbsp;On Monday,&nbsp;<a href="https://stocktwits.com/symbol/REPL">REPL</a> fell 64%,&nbsp;<a href="https://stocktwits.com/symbol/HOTH">HOTH</a> slipped 1% and&nbsp;<a href="https://stocktwits.com/symbol/ONCO">ONCO</a> declined 27%, while the Health Care Select Sector SPDR Fund (XLV) rose 0.5%.<h2 class="st-heading-2">Regulatory Setback Pressures REPL Shares Again</h2>Pressure on REPL intensified recently after the U.S. Food and Drug Administration (FDA) issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with Nivolumab in anti-PD-1-failed melanoma, extending regulatory uncertainty that had already followed an earlier CRL last year.The latest development triggered a wave of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-on-track-to-hit-all-time-lows-here-s-why-this-analyst-slashed-price-target-by-85/cZJFHklRIMD">analyst downgrades</a> across Wall Street. Jefferies said the company faces “a tough road ahead” following the FDA’s response, while BMO Capital said the CRL “lays bare the lack of alignment with the FDA and Replimune” throughout clinical development and warned the revised regulatory pathway may now require additional trials.JPMorgan called the outcome “disappointing,” adding it had previously believed “the totality of the data for RP1 warranted an approval.”&nbsp;<h2 class="st-heading-2">Stock Offering Weighs On HOTH Stock</h2>HOTH declined after the company announced earlier this month a stock offering priced at $0.7 per share, expected to generate about $2 million in gross proceeds before expenses, along with warrants exercisable at $0.85.The financing overshadowed pipeline updates over the past month, when the company reported interim Phase 2 progress for HT-001, a topical therapy to treat skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitor cancer treatments. The trial showed that patients reached the primary efficacy endpoint by the sixth week and demonstrated “strong patient benefit across multiple clinically meaningful measures.”&nbsp;However, shares caught a break in after-hours trading on Monday, jumping over 60%, after preclinical data showed its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-hoth-stock-up-after-hours-today/cZJ8gnKRIuz">HT-VA (GDNF) therapy</a> improved key gene markers linked to fat production and metabolism and outperformed Novo Nordisk's semaglutide on liver-fat regulation signals.<h2 class="st-heading-2">ONCO Slides Despite Realbotix Merger Progress</h2>ONCO shares have remained weak since the company implemented a 1-for-5 reverse stock split, effective March 25, to maintain compliance with Nasdaq’s minimum bid price requirement.The reverse split followed a September equity raise of $12.9 million through Series D preferred stock and warrants, with proceeds used in part to reduce outstanding debt and support working capital following the termination of a previously planned merger with Ocuvex.In February, the company entered into an agreement to acquire Realbotix in an all-stock transaction expected to close in the second half of 2026. Realbotix reported delivering its first Vinci-equipped humanoid robot to Ericsson this month and said the platform enables robots to “recognize returning users, recall previous conversations, and track engagement.” The company expects deliveries of 19 robots across March, April and May as production scales.<h2 class="st-heading-2">How Do Retail Traders Feel About REPL, HOTH, ONCO?</h2>On Stocktwits, retail sentiment for REPL was ‘bearish’ amid ‘extremely high’ message volume, while sentiment for both HOTH and ONCO remained ‘extremely bullish,’ also accompanied by ‘extremely high’ message volume.Over the past year, REPL has fallen 77%, HOTH down 36% and ONCO declining 97%, with all three stocks underperforming the broader XLV ETF, which rose 10% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-founder-fda-warning-letter-anktiva-ad-never-aired/cZJpYnYRIHR">ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All'</a>

On Monday alone, REPL plunged 64%, ONCO dropped 27%, and HOTH slipped 1%. (Photo credit: Getty Images)

REPL, HOTH, ONCO Stocks Hit 52-Week Lows: What's Driving The Selloff In These Biotech Plays?

On Monday alone, REPL plunged 64%, ONCO dropped 27%, and HOTH slipped 1%, underperforming the broader XLV healthcare ETF.

Equity

In this photo illustration, a smartphone displays the logo of UnitedHealth Group Incorporated. (Photo illustration by Cheng Xin/Getty Images)

UNH Vs. HUM: Which Insurer Stock Has More Upside After CMS Reverses Wall Street’s Biggest Medicare Rate Fear?

Analyst sentiment remains more favorable toward UnitedHealth, while Humana’s coverage is largely skewed toward ‘Hold’ ratings.

Likely Sector ETF & Stock Winners From March Jobs Report 

March jobs data highlights sector winners -- Healthcare, Transport & Construction ETFs gain as hiring rebounds and steady demand supports growth.

Consumer Sentiment Weakens: ETFs That Are Worth a Look

Rising oil prices and Middle East tensions are squeezing household finances and weakening consumer sentiment, steering investors toward defensive ETFs.

Stagflation Scare? ETFs May Help Protect Your Portfolio

Are stagflation risks returning as oil-driven inflation rises amid Middle East tensions? Here's how ETFs can help defend portfolios.

Pressure Mounts on U.S. Consumers Amid Middle East Conflict: ETFs to Watch

Middle East tensions and rising oil prices are weighing on U.S. consumers, dragging down confidence and pushing investors toward defensive ETFs.

Middle East Turmoil and U.S. Debt Surge: ETFs in Focus

With U.S. budget deficits and already elevated debt, the ongoing Middle East war could worsen the fiscal outlook, making defensive ETF strategies worth considering for stability.

XLV, UNH, TMO, PFE: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have...

<ul class="summary-bullets"><li>The clinical trial included 36 participants who continued taking existing medications for generalized anxiety disorder while receiving HLP004 injections.</li><li>Researchers administered two doses three weeks apart and monitored participants for 12 weeks.</li><li>Six months after treatment, about 67% of the combined study group met the criteria for a clinical response.</li></ul>Helus Pharma (HELP) announced encouraging early-stage clinical results for its experimental anxiety treatment HLP004 on Thursday, reporting notable symptom improvement among patients with moderate-to-severe generalized anxiety disorder.&nbsp;The clinical-stage drug developer said its Phase 2 signal detection trial showed statistically meaningful improvements when the therapy was used alongside standard antidepressant treatments.&nbsp;<h2 class="st-heading-2">Trial Demonstrates Significant Anxiety Reduction</h2>In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks.&nbsp;The clinical trial included 36 participants who continued taking existing medications for generalized anxiety disorder while receiving HLP004 injections. Researchers administered two doses, three weeks apart, and monitored participants for 12 weeks, with additional follow-up planned for up to 1 year.<a href="https://stocktwits.com/symbol/HELP">Helus Pharma stock</a> traded over 22% lower in Thursday’s remarket.&nbsp;<h2 class="st-heading-2">Long-Lasting Response Observed In Many Patients</h2>The company also reported sustained benefits beyond the initial treatment period. Six months after treatment, about 67% of the combined study group met the criteria for a clinical response, while 39% reached remission.Among those receiving the higher 20-milligram dose, 59% showed improvement and 32% achieved remission after six weeks. In the lower-dose group, about 30% of patients met response and remission benchmarks at the same time point.<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>Despite the stock’s decline in the premarket session, retail sentiment on Stocktwits around the stock flipped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_083359_png_25a9744605.webp" alt="HELP’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="925" height="96"><figcaption>HELP’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they have bought the dip.&nbsp;<stembedurl>https://stocktwits.com/Jimbob3016/message/646658779</stembedurl>HELP stock has gained over 4% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/liquidia-stock-gains-premarket-on-q4-revenue-beat-investors-are-betting-on-yutrepia-growth/cZdQrwNRI33">Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism

In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks. 

<ul class="summary-bullets"><li>Revenue recognized under the Sanofi agreement, including milestone and royalty payments, amounted to $98 million in Q4.</li><li>The company recorded net income of $18 million during the quarter, compared to an $81 million loss during the year-ago period.</li><li>Selling, general, and administrative expenses fell 53% year-over-year.&nbsp;</li></ul>Novavax, Inc. (NVAX) reported a sharp increase in fourth-quarter (Q4) and 2025 revenue as the vaccine maker leaned on partnership income, cost cuts and product sales.The Maryland-based biotech generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. Both the metrics surpassed the analysts’ consensus estimates of $90.26 million and a loss of $0.55, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Q4 Performance Highlights</h2>Annual revenue surged 65% YoY to $1.12 billion, driven in large part by $625 million in Nuvaxovid sales linked primarily to settlements of earlier advance purchase deals.Quarterly product sales totaled $39 million, while full-year product sales rose to $685 million. Revenue recognized under the Sanofi agreement, including milestone and royalty payments, amounted to $98 million in Q4 and $386 million for the year. The company said it earned $225 million in milestones from the Sanofi collaboration in 2025.<blockquote>"In 2025, we made significant progress on our corporate strategy, marked with the successful achievement of key milestones under our Sanofi agreement, progress towards potential new partnerships, in the form of multiple MTAs signed with other parties enabling experimentation with our Matrix-M adjuvant technology and the advancement of our own R&amp;D efforts.”-John C. Jacobs, President and CEO, Novavax</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax stock</a> traded over 1% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;&nbsp;<h2 class="st-heading-2">Costs Fall As Profitability Improves</h2>Novavax reduced its cost of sales to $22 million in the fourth quarter from $37 million a year earlier. The decline followed the divestiture of its Czech manufacturing site and lower overhead and inventory-related charges.Selling, general, and administrative expenses fell more than half YoY as commercial responsibilities transitioned to Sanofi and infrastructure was streamlined. The company recorded net income of $18 million in Q4, compared to an $81 million loss during the year-ago period. Novavax ended 2025 with $751 million in cash and equivalents.&nbsp;NVAX stock has gained ovr 0% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-falls-premarket-es8-demand-powers-through-chip-shortage/cZTG3ncRIbK">Nio Stock Falls Premarket: Flagship ES8 Demand Powers Through Fresh Chip Shortage Disruption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue 

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XLV News

XLVHealth Care Select Sector SPDR Fund